Andere talen Outlook Therapeutics, Inc.

Aandelen

OTLK

US69012T3059

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,15 ^USD	-0,69%		+1,13%	-9,26%

28/05	Outlook Therapeutics verleent EU-markttoelating voor Lytenava voor de behandeling van natte AMD	MT
28/05	Outlook Therapeutics, Inc. Ontvangt toestemming van de Europese Commissie voor het in de handel brengen van LYTENAVA? (bvacizumab grapa) voor de behandeling van natte AMD	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	12/06
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	11/06
European Biosimilar Regulatory Update	10/06
Corporate Presentation: June 2024	05/06
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	29/05
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	28/05
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	28/05
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	28/05
CoStar Group has room for expansion	21/05
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	15/05
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	13/05
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	13/05
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	09/05
Outlook Therapeutics® to Present at the Retina World Congress 2024	02/05
Outlook Therapeutics, Inc. Announces Change in Headquarters Address	01/05
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	15/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Outlook Therapeutics, Inc.

Aandelen

OTLK

US69012T3059

Andere talen

Filters